Safety, PK, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction

Overview

– To evaluate pharmacokinetics (PK) of omecamtiv mecarbil in Japanese subjects with heart failure (HF) with reduced ejection fraction – To evaluate the safety and tolerability of oral omecamtiv mecarbil

Full Title of Study: “A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Omecamtiv Mecarbil in Japanese Subjects With Heart Failure With Reduced Ejection Fraction”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: April 6, 2017

Detailed Description

This study was conducted by Amgen as the IND holder, with Cytokinetics as a collaborator. Due to the termination of the collaboration agreement between Amgen and Cytokinetics in May 2021 and subsequent transfer of the omecamtiv mecarbil IND from Amgen to Cytokinetics, Cytokinetics is now listed as the sponsor.

Interventions

  • Drug: 25 mg Omecamtiv Mecarbil
    • oral tablet
  • Drug: Placebo
    • oral tablet
  • Drug: 37.5 mg Omecamtiv Mecarbil
    • oral tablet
  • Drug: 50 mg Omecamtiv Mecarbil
    • oral tablet

Arms, Groups and Cohorts

  • Placebo Comparator: Placebo BID
    • Participants will receive placebo BID.
  • Experimental: 25 mg Omecamtiv Mecarbil BID
    • Participants will receive 25 mg omecamtiv mecarbil BID.
  • Experimental: 37.5 mg Omecamtiv Mecarbil BID Target Dose
    • Participants will receive omecamtiv mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 37.5 mg BID after Week 4 or Week 8, based on Week 2 PK.
  • Experimental: 50 mg Omecamtiv Mecarbil BID Target Dose
    • Participants will receive Omecamtiv Mecarbil 25 mg BID up to Week 4 or Week 8 and 25 mg or 50 mg BID after Week 4 or Week 8, based on Week 2 PK.

Clinical Trial Outcome Measures

Primary Measures

  • Pharmacokinetics (PK): Concentration Before Morning Dose (Cpredose) Over Time
    • Time Frame: Before morning dose on Week 2 (Day 15), Week 4 (Day 28), Week 12 (Day 84), Week 16 (Day 112)
  • PK: Area Under the Curve Until 8 Hours After Morning Dose at Week 8 (AUC0-8)
    • Time Frame: Week 8 (Day 56) at predose, at 2 hours ±30 minutes; 4 hours ±30 minutes; 6 hours ±30 minutes; 8 hours ±30 minutes after morning dose

Secondary Measures

  • Change From Baseline at Week 16 in Systolic Ejection Time (SET)
    • Time Frame: Baseline, Week 16 (Day 112)
    • LS mean was from the repeated measures model, which included treatment group, stratification factor (from IVRS), scheduled visit, baseline value, and the interaction of treatment group with scheduled visit as covariates.

Participating in This Clinical Trial

Inclusion Criteria

  • Japanese male or female ≥ 20 years and ≤ 85 years of age – History of chronic stable heart failure (HF) with reduced ejection fraction, defined as requiring treatment for HF for a minimum of 4 weeks prior to screening – Treated for HF with optimal pharmacological therapy – Left ventricular ejection fraction ≤ 40% at screening Exclusion Criteria:

  • Severe uncorrected valvular heart disease – Hypertrophic obstructive cardiomyopathy, active myocarditis, constrictive pericarditis, or clinically significant congenital heart disease – Acute myocardial infarction, unstable angina, or persistent angina at rest within 30 days prior to randomization – Systolic blood pressure (BP) > 160 mmHg or < 90 mmHg, or diastolic BP > 90 mmHg, or heart rate (HR) > 110 beats per minute (bpm) or HR < 50 bpm – Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m^2 – Total bilirubin (TBL) ≥ 2x upper limit of normal (ULN), or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) ≥ 3x ULN Other Exclusion Criteria may apply.

Gender Eligibility: All

Minimum Age: 20 Years

Maximum Age: 85 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • Cytokinetics
  • Provider of Information About this Clinical Study
    • Sponsor
  • Overall Official(s)
    • MD, Study Director, Amgen

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.